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Aims PCSK9 loss of function genetic variants are associated with lower low-density lipoprotein cholesterol but also with
15 higher plasma glucose levels and increased risk of Type 2 diabetes mellitus. Here, we investigated the molecular
mechanisms underlying this association.
...................................................................................................................................................................................................
Methods
and results
20 Pcsk9 KO, WT, Pcsk9/Ldlr double KO (DKO), Ldlr KO, albumin AlbCreþ/Pcsk9LoxP/LoxP (liver-selective Pcsk9 knock-
out mice), and AlbCre-/Pcsk9LoxP/LoxP mice were used. GTT, ITT, insulin and C-peptide plasma levels, pancreas
morphology, and cholesterol accumulation in pancreatic islets were studied in the different animal models. Glucose
clearance was significantly impaired in Pcsk9 KO mice fed with a standard or a high-fat diet for 20 weeks compared
with WT animals; insulin sensitivity, however, was not affected. A detailed analysis of pancreas morphology of
25 Pcsk9 KO mice vs. controls revealed larger islets with increased accumulation of cholesteryl esters, paralleled by
increased insulin intracellular levels and decreased plasma insulin, and C-peptide levels. This phenotype was com-
pletely reverted in Pcsk9/Ldlr DKO mice implying the low-density lipoprotein receptor (LDLR) as the proprotein
convertase subtilisin/kexin Type 9 (PCSK9) target responsible for the phenotype observed. Further studies in albu-
min AlbCreþ/Pcsk9LoxP/LoxP mice, which lack detectable circulating PCSK9, also showed a complete recovery of the
30 phenotype, thus indicating that circulating, liver-derived PCSK9, the principal target of monoclonal antibodies, does
not impact beta-cell function and insulin secretion.
...................................................................................................................................................................................................
Conclusion PCSK9 critically controls LDLR expression in pancreas perhaps contributing to the maintenance of a proper
35 physiological balance to limit cholesterol overload in beta cells. This effect is independent of circulating PCSK9 and
is probably related to locally produced PCSK9.
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PCSK9 (proprotein convertase subtilisin/kexin Type 9) is a protein,
mainly synthesized and secreted by the liver, which binds to specific
proteins and escorts them to endosomes/lysosomes compartments
5 for degradation.1,2 The low-density lipoprotein receptor (LDLR) has
been identified as the main target of PCSK93; mice lacking Pcsk9 ex-
hibit an increased hepatic LDLR expression, resulting in an increased
clearance of circulating low-density lipoprotein (LDL) and hypocho-
lesterolaemia,4 while PCSK9 overexpression induces a two-fold in-
10 crease in plasma cholesterol levels.5
In humans, several mutations in PCSK9 gene were described, with
‘gain-of-function’ mutations associated to familial hypercholesterol-
aemia (FH)6 and ‘loss of function’ mutations linked to low-LDL-chol-
esterol (LDL-C) levels.7,8
15 On these premises, anti-PCSK9 therapies have been developed,
and monoclonal antibodies against PCSK9 are available for the treat-
ment of patients with severe hypercholesterolaemia and/or very high
cardiovascular risk.
While the liver is the main contributor to circulating PCSK9,9
20 other tissues produce PCSK9 pointing to a possible role of this pro-
tein beyond the control of LDLR expression in the liver.1,10
Of note, the LDLR is abundantly expressed by pancreatic b cells in
humans, mice, and rats, where it plays a key role in the uptake of plasma
LDL.11,12 Cholesterol homeostasis is crucial for b cells function and
25 survival; excessive cholesterol accumulation causes a significant reduc-
tion in the islets’ ability to secrete insulin in response to glucose,13 and
prolonged exposure to high levels of LDL or very low-density lipopro-
tein could also be lethal for b cells.12,14 Increased LDLR expression and
cholesterol content were observed in the pancreas of Pcsk9-deficient
30 mice,15,16 suggesting also a potential role for the protein in this tissue.
Interestingly, in three different Mendelian randomization studies, the
analysis of the effects of genetic scores consisting of independently
inherited polymorphisms in the PCSK9 gene resulted into reduced
LDL-C levels and cardiovascular events but was also associated with an
35 increased risk of diabetes17–19; furthermore, patients with FH
(decreased LDLR function) appear to have a lower risk of diabetes.20
On this background, we investigated the molecular mechanisms
beyond the impaired glucose metabolism observed in PCSK9-defi-
cient state and tested (i) whether the absence of the LDLR rescues
40 the phenotype by studying Pcsk9/Ldlr double KO (DKO) mice and (ii)
the role of circulating/liver-derived PCSK9.
Here, we show that PCSK9 deficiency is associated with impaired
glucose tolerance in mice, which appears to be the consequence of
decreased insulin secretion from the pancreas rather than insulin
45resistance. This effect appears to be largely independent from liver-
derived PCSK9.
Materials and methods
A detailed description of mice, dietary regimens, glucose tolerance and in-
sulin tolerance tests, pancreatic islet staining, western blot analysis, ana-
50lysis of cholesterol accumulation in pancreatic islets, bioinformatics, and
statistical analysis is presented as the Supplementary material online.
Results
Pcsk9 deficiency is associated with
impaired glucose tolerance but not with
55insulin resistance
To evaluate the effect of PCSK9 on plasma glucose, mice were fed
with a standard fat diet (SFD) or a high-fat diet (HFD) for 20 weeks.
Despite similar plasma glucose levels at baseline, following glucose
tolerance test (GTT), the absence of PCSK9 resulted in a significant
60delay of glucose clearance in both the SFD (Figure 1A–D) or the HFD
(Figure 1E–H) groups after 12 or 20 weeks of diet. The plasma glucose
area under the curve (AUC) in all conditions was significantly higher
in Pcsk9 KO mice compared with WT (Figure 1C, D, G, and H). The
observation that Pcsk9 KO mice presented glucose intolerance fol-
65lowing GTT in spite of similar baseline glucose levels (following over-
night fasting) prompted us to perform a fast and refeeding
experiment to better understand possible differences in plasma glu-
cose levels under physiological conditions.
After overnight fasting and ad libitum refeeding (4 h), Pcsk9 KO
70mice presented a significant increase in plasma glucose levels com-
pared with WT littermates (268± 6 mg/dL for Pcsk9 KO compared
with 219 ± 30 mg/dL for WT mice, P= 0.008) in spite of similar food
consumption (2.27± 0.43 g/4 h vs. 2.18 ± 0.38 g/4 h). This observa-
tion confirmed the presence of impaired glucose tolerance in Pcsk9
75KO mice and set the stage for investigating whether this effect was
the consequence of impaired insulin tolerance.
Insulin tolerance test (ITT) was performed in WT and Pcsk9 KO
mice, after a 4 h fast. The animals were injected with insulin (0.2 IU/kg
body weight) intraperitoneally. The decrease in plasma glucose levels
80was similar in WT and Pcsk9 KO mice fed with an SFD (Figure 2A and
B) or an HFD (see Supplementary material online, Figure S1A and B)
for 12 or 20 weeks, thus excluding the presence of insulin resistance
in the Pcsk9-deficient state. To further extend this finding, we meas-
ured the ratio between phosphorylated Akt vs. total Akt as an index
Translational perspective
Mendelian randomization studies have shown that PCSK9 genetic variants associate with lower low-density lipoprotein cholesterol
but higher fasting plasma glucose levels and increased risk of Type 2 diabetes. The investigation of molecular mechanisms responsible
for this effect demonstrated that the deficiency of locally but not of circulating proprotein convertase subtilisin/kexin Type 9
(PCSK9) is responsible for increased low-density lipoprotein receptor expression in pancreatic islets, which results in cholesterol
accumulation and beta-cell dysfunction. These data suggest that anti-PCSK9 therapies, which target mainly circulating PCSK9, might
have a limited impact on beta-cell dysfunction and the incidence of diabetes in contrast to Mendelian randomization analysis, where
the effect of global PCSK9 deficiency was investigated.
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Figure 1 Pcsk9 deficiency is associated with impaired glucose tolerance. Intraperitoneal glucose tolerance test was performed, and plasma glucose
levels were measured at 0, 20, 40, 60, and 120 min. (A) Data obtained from mice fed with a standard fat diet for 12 weeks (0 min, P= 0.426; 20 min,
*P= 0.038; 40 min, *P= 0.006; 60 min, *P= 0.028; 120 min, P= 0.488) are shown. (B) Data obtained from mice fed with a standard fat diet for
20 weeks (0 min, P= 0.702; 20 min, P= 0.104; 40 min, *P= 0.038; 60 min, *P= 0.041; 120 min, P= 0.062) are shown. (C) The AUC of intraperitoneal
glucose tolerance test performed on mice fed for 12 weeks with a standard fat diet (*P= 0.015) are shown. (D) The AUC of intraperitoneal glucose
tolerance test performed on mice fed for 20 weeks with a standard fat diet (*P= 0.021) are shown. (E) Data obtained from mice fed with a high-fat
diet for 12 weeks (0 min, P= 0.865; 20 min, *P= 0.013; 40 min, *P= 0.034; 60 min, *P= 0.022; 120 min, *P= 0.012) are shown. (F) Data obtained from
mice fed with high-fat diet for 20 weeks (0 min, P= 0.702; 20 min, P= 0.073; 40 min, P= 0.125; 60 min, *P= 0.001; 120 min, *P= 0.002) are shown. (G)
The AUC of intraperitoneal glucose tolerance test performed on mice fed for 12 weeks with high-fat diet (*P= 0.001) are shown. (H) The AUC of
intraperitoneal glucose tolerance test performed on mice fed for 20 weeks with high-fat diet (*P= 0.003) are shown. Data are shown as mean ±
standard deviation; n= 8 mice per all group.
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..of downstream activation of the insulin receptor21 in the liver and in
the soleus muscle before and 30 min after intraperitoneal insulin in-
jection in mice fed with an SFD for 4 months. pAkt S473/Akt ratio or
pAktT308/Akt ratio was similar in WT and Pcsk9 KO mice (see
5 Supplementary material online, Figure S2A and B) under basal and fol-
lowing IP insulin injection, suggesting that downstream activation of
insulin receptor is not affected by Pcsk9 deficiency.
Pcsk9 deficiency results in impaired
insulin secretion and histological
10 abnormalities in pancreatic islets
We then investigated whether Pcsk9 deficiency affects insulin produc-
tion and pancreatic b-cell function. Plasma insulin and C-peptide
levels were significantly decreased in Pcsk9 KO mice compared with
WT littermates (Figure 2C); a similar profile was observed in HFD-fed
15mice (see Supplementary material online, Figure S1C). Following fast-
ing and refeeding experiments, a reduced increment in plasma insulin
levels in Pcsk9 KO mice was observed vs. WT mice (Figure 2D).
Similarly, following IP glucose injection, plasma insulin levels increased
to a lower extent in Pcsk9 KO mice compared with WT animals (see
20Supplementary material online, Figure S1D). We next evaluated
whether the phenotype observed in Pcsk9 KO mice could also be the
consequence of altered incretins production. GLP1 and GIP plasma
levels in fasted and refed conditions were similar in WT and Pcsk9
KO mice (Figure 2E and F). The same was true when incretin’s levels
25were measured following an oral bolus of glucose (see
Supplementary material online, Figure S1E and F). In contrast to
A B
C D
E F
Figure 2 Pcsk9 deficiency is not associated with insulin resistance but with impaired insulin secretion. Intraperitoneal insulin tolerance test was per-
formed, and plasma glucose levels were measured at 0, 20, 40, 60, and 120 min. (A) Data obtained from mice fed with a standard fat diet for 12 weeks
(0 min, P= 0.858; 20 min, P= 0.323; 40 min, P= 0.495; 60 min, P= 0.817; 120 min, P= 0.521) are shown. (B) Data obtained from mice fed with a stand-
ard fat diet for 20 weeks (0 min, P= 0.899; 20 min, P= 0.206; 40 min, P= 0.138; 60 min, P= 0.275; 120 min, P= 0.524) are shown. Data are shown as
mean ± standard deviation; n= 8 mice per group. (C) Plasma insulin and C-peptide levels in Pcsk9 KO compared to WT mice (*P= 0.047 and
*P= 0.009, respectively) are shown. Plasma insulin levels following fasting (overnight) and refeeding (4 h) experiment are presented in (D) (*P= 0.047
vs. WT fasted; #P= 0.002 vs. WT fed, and $P= 0.002 vs. Pcsk9 KO fasted). (E and F) Plasma levels of GLP-1 and GIP following fasting (overnight) and
refeeding (4 h) are shown. Data are shown as mean ± standard deviation; n= 6 mice per group.
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decreased circulating levels, we observed that pancreatic insulin con-
tent was significantly increased in Pcsk9 KO mice compared with WT
mice (Figure 3A) (see Supplementary material online, Figure S1G).
These data suggest that Pcsk9 mutant KO mice might have a defective
5 insulin secretion, which could lead to an increased accumulation in
beta cells. We, therefore, studied pancreatic islets morphology and
observed that islets from Pcsk9 KO mice present with irregular shape
(Figure 3B and Supplementary material online, Figure S3A). A detailed
analysis of consecutive pancreatic sections from three different
10 regions of each pancreas (see Supplementary material online, Figure
S3B) showed larger islet size (Figure 3C) together with a significant in-
crease in the major and minor axis of each islet in the pancreas of
Pcsk9 KO mice compared with WT mice (Figure 3D and E). These
findings were paralleled by a different islet size distribution between
15Pcsk9 KO and WT mice (Figure 3F).
To further extend these data in humans, we investigated the im-
pact of the PCSK9 46L variant on the homeostasis model assessment:
insulin resistance (HOMA-IR) and beta-cell function (HOMA-BC).
HOMA-BC but not HOMA-IR was significantly lower in carriers of
20the PCSK9 46L variant compared with carriers of the wild-type allele
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Figure 3 Histological characterization of pancreatic islets from Pcsk9 KO mice. Pancreatic insulin content in Pcsk9 KO and WT mice is shown in
panel (A) (*P= 0.004). Data are shown as mean ± standard deviation; n= 6 mice per each group. Pancreatic islets morphology shows larger islets in
Pcsk9 KO mice compared with WT (B–F). A representative image is presented in panel (B) (scale bar: 20lm). Panel (C) shows pancreatic islet size
(*P< 0.001), while panels (D and E) show minor and major axis of each islet analysed (*P< 0.001 and *P< 0.001, respectively). In (F), islet size distribu-
tion, as percentage of total islets analysed, is shown. Islets were categorized according to the surface area (seven categories: from <10 000 lm2 to
>60 000 lm2). Data shown in panels (C–F) were obtained from the analysis of 24 sections and 100 fields for each pancreas (mean ± standard devi-
ation, n= 7 per group).
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(see Supplementary material online, Figure S4A and B) indicating that
under PCSK9-deficient conditions, impaired b-cell functionality
occurs also in humans.
These data suggest a relationship between PCSK9 deficiency and
5 insulin secretion and prompted us to investigate the molecular mech-
anisms responsible for this effect.
PCSK9 effect on glucose metabolism is
dependent on the presence of the low-
density lipoprotein receptor
10 The LDLR is abundantly expressed also on the surface of pancreatic
b cells where it plays a key role in the uptake of LDL.9,10 Increased
beta-cell cholesterol levels were associated with decreased insulin se-
cretion.22–24 The analysis of pancreatic sections from WT and Pcsk9
KO mice showed that LDLR is present mainly in b cells (Figure 4A and
15 Supplementary material online, Figure S5A), and as detected by west-
ern blot analysis (Figure 4B and C) and FACS analysis (Figure 4D and
Supplementary material online, Figure S5B), its expression is increased
in pancreatic islets isolated from Pcsk9 KO animals compared with
WT mice.
20 We next explored whether the increase in LDLR expression
might be reflected in changes in pancreatic islets lipid content.
Indeed, Pcsk9 KO mice islets presented higher cholesterol esters lev-
els compared with WT islets, together with significant changes in fatty
acid lipidome (Figure 4E). This lipid profile was paralleled by the
25 down-regulation of genes involved in cholesterol biosynthesis and
uptake, including HMGCoA-R and LDLR, the increase of the expres-
sion of ACAT1, which promotes cholesterol esterification (Figure 4F)
and a non-significant increase in genes involved in cholesterol efflux
(Figure 4F) and ABCA-1 protein expression (data not shown).
30 Moreover, a similar expression of Annexin V, a marker of apoptosis,
was observed in b cells from both animal models (see Supplementary
material online, Figure S5C) suggesting that, in vivo and at the time
point analysed, cholesterol accumulation induces b-cell dysfunction
before inducing cellular toxicity.
35 As expected,25 plasma cholesterol levels were decreased in Pcsk9
KO mice compared with WT with most of the cholesterol trans-
ported on HDL (see Supplementary material online, Figure S6A
and B).
To further test the hypothesis that the observed phenotype in
40 Pcsk9 KO mice could be dependent on the impact on LDLR, GTT
and ITT were evaluated in Pcsk9/Ldlr DKO mice and Ldlr KO animals.
The delayed glucose response observed in Pcsk9-deficient conditions
was not observed in SFD-fed Pcsk9/Ldlr DKO mice, and, indeed, GTT
and ITT curves were superimposable between the two animal groups
45 (Figure 5A and B) and similar to those observed in WT animals. Also,
fast and refeeding experiments resulted in similar plasma glucose lev-
els (190± 15 mg/dL for Pcsk9/Ldlr DKO compared with 191± 16 mg/
dL for Ldlr KO mice).
Moreover, DKO mice and Ldlr KO littermates were characterized
50 by similar levels of both plasma and pancreatic insulin levels
(5.27± 2.78 ng/mL vs. 4.67 ± 3 ng/mL, P= 0.666) (71.5 ± 64 ng/mg of
tissue vs. 77.7 ± 56.6 ng/mg of tissue, P= 0.531) (Figure 5C and D).
Pancreatic islets morphology was similar in both animal groups com-
pared with WT (Figure 5E and F) as was pancreatic islets cholesterol
55 esters content (see Supplementary material online, Figure S7A),
indicating that the PCSK9/LDLR axis could explain the phenotype
observed in Pcsk9-deficient animals.
Circulating PCSK9 does not impact
glucose metabolism and beta-cell
60function
In humans, PCSK9 is mostly produced by the liver but is also synthe-
sized to a relevant amount in the brain, the intestine, the lung, and the
pancreas (Figure 6A). Pancreatic islets analysis in WT mice showed, in
line with previous findings,26 that PCSK9 is expressed in d cells but is
65under the level of detection in a or b cells (Figure 6B and
Supplementary material online, Figure S7B). To dissect out the role of
circulating, liver-derived PCSK99 from that of locally produced pro-
tein, we tested glucose metabolism in SFD-fed liver-specific Pcsk9 KO
mice. PCSK9 protein was not detectable in plasma from AlbCreþ/
70Pcsk9LoxP/LoxP, while in AlbCre-/Pcsk9LoxP/LoxP mice, plasma
PCSK9 levels were 10.2± 4.2 mg/dL. PCSK9 mRNA expression was
almost abolished in the liver from AlbCreþ/Pcsk9LoxP/LoxP, while
mRNA and protein expression in pancreas were similar between
AlbCreþ/Pcsk9LoxP/LoxP and AlbCre-/Pcsk9LoxP/LoxP mice (Figure
756C and D), confirming the liver specificity of the KO model.
Furthermore, plasma cholesterol levels in AlbCreþ/Pcsk9LoxP/LoxP
mice were significantly lower compared with AlbCre-/Pcsk9LoxP/
LoxP (41.8± 7.6 mg/dL vs. 68.5± 10.1 mg/dL, P= 0.013) and similar to
those observed in Pcsk9 KO mice (51.1 ± 14.0 mg/dL), further con-
80firming the key role of liver derived, circulating PCSK9 on plasma chol-
esterol levels. The LDLR expression (Figure 6E, and Supplementary
material online, Figure S8A) was similar in pancreatic islets from
AlbCreþ/Pcsk9LoxP/LoxP and AlbCre-/Pcsk9LoxP/LoxP mice as
were lipid levels in pancreatic islets (see Supplementary material on-
85line, Figure S8B). AlbCre-/Pcsk9LoxP/LoxP mice presented similar
GTT and ITT curves (Figure 6F and G), and the same was true for
plasma glucose levels following fast and refeeding experiments
(194 ± 8 mg/dL for AlbCreþ/Pcsk9LoxP/LoxP mice compared with
192± 5 mg/dL for AlbCre-/Pcsk9LoxP/LoxP mice). Also pancreatic in-
90sulin levels were similar in the two animal models (133.6± 47.16 ng/
mg of tissue vs. 119.1± 43.2 ng/mg of tissue for AlbCreþ/Pcsk9LoxP/
LoxP and AlbCre-/Pcsk9LoxP/LoxP mice; P= 0.629). These data sug-
gest that circulating, liver-derived PCSK9 does not impact LDLR ex-
pression in pancreas.
95Discussion
Mendelian randomization studies have recently shown that PCSK9
genetic variants associated with lower LDL cholesterol are also asso-
ciated with circulating higher fasting glucose concentration and an
increased risk of Type 2 diabetes.17–19 Here, we describe in experi-
100mental models, a possible mechanism beyond this causal association
and identify LDLR in the pancreatic islets as the potential target of lo-
cally produced PCSK9.
The accumulation of cholesterol in pancreatic islets has been asso-
ciated with reduced glucose induced insulin secretion13 and cellular
105toxicity22–24 pointing to the critical role of cholesterol metabolism in
pancreas. Cholesterol influx in b cells mainly results from LDL uptake
through the LDLR,14 the latter is largely expressed in these cells.11 As
a consequence, genetic and acquired conditions increasing LDLR
6 L. Da Dalt et al.
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Figure 4 Low-density lipoprotein receptor expression is increased in pancreatic islets from Pcsk9 KO mice. (A) A representative picture of pancre-
atic islets from WT and Pcsk9 KO animals stained for insulin (red), somatostatin (blue), and LDLR (green) are shown. The right part of the panel
shows a selected area at higher magnification (2). The insulin staining was used as a marker for b cells and the yellow staining indicates co-expres-
sion of insulin and low-density lipoprotein receptor in the same cells, arrowheads highlight the membrane staining of low-density lipoprotein recep-
tor in Pcsk9 KO mice. For each image, the maximum intensity projection of serial confocal sections is shown. Scale bar: 20lm. (B) A representative
image of immunoblotting analysis for LDLR in pancreatic islets isolated from Pcsk9 KO, WT, and Ldlr KO mice are shown. (C) The quantification of
western blot analysis for low-density lipoprotein receptor expression in pancreatic islets isolated from Pcsk9 KO mice compared with WT mice are
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Figure 5 PCSK9 effect on glucose metabolism is dependent on the low-density lipoprotein receptor. (A) Plasma glucose levels in Pcsk9/Ldlr DKO
and in Ldlr KO mice following intraperitoneal glucose tolerance test (0, 20, 40, 60, and 120 min) (12 weeks of diet) are shown. (B) Plasma glucose lev-
els in Pcsk9/Ldlr DKO and in Ldlr KO mice following intraperitoneal insulin tolerance test (0, 20, 40, 60, and 120 min) are shown. (C) Plasma insulin lev-
els and (D) pancreatic insulin levels in Pcsk9/Ldlr DKO and in Ldlr KO mice are shown. (E) A representative image of pancreatic islet morphology,
while (F) presents data on pancreatic islets size are shown. For each mouse, 24 sections and 100 fields were imaged and analysed. Data in panels
(A–D) are shown as mean ± standard deviation; n= 5 mice per group (no significant differences were observed between groups P> 0.05).
Figure 4 Continued
shown (data are shown as mean ± standard deviation, n= 6 per group, *P= 0.047). (D) The mean fluorescence intensity of FACS analysis for
low-density lipoprotein receptor expression in pancreatic islets isolated from WT animals (red curve), Pcsk9 KO mice (blue curve) com-
pared with that of Ldlr KO (green curve) are shown. (E) Cholesterol esters and fatty acids content in pancreatic islets from Pcsk9 KO and
WT mice (Chol, *P= 0.004; 16: 0, *P= 0.011; 16: 1, *P= 0.026; 18: 2, *P= 0.04; unpaired t-test; n= 3 mice per group) are shown. (F) The ex-
pression of genes related to cholesterol biosynthesis, uptake, and efflux, and the expression of ACAT1 in pancreatic islets from Pcsk9 KO
and WT mice (HMGCoA, *P= 0.045; LDLR, *P= 0.048; ACAT1, *P= 0.03 t-test; n= 6 mice per group) are shown. Data are shown as mean
± standard deviation.
8 L. Da Dalt et al.
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Figure 6 Circulating PCSK9 does not impact glucose metabolism and b-cell function. (A) PCSK9 gene expression in human tissues according to the
Genotype–Tissue Expression (GTEx) portal are shown. Data are reported as RPKM (Reads per Kilobase per Million mapped reads): 12.775 RPKM in
the liver, 9.098 RPKM in the brain (cerebellum), 3.362 RPKM in the lung, 1.874 in the small intestine, 1.578 in the pancreas, 1.263 in colon (transverse),
0.577 in the nerve (tibial), 0.287 in cells (transformed fibroblasts), and 0.108 in the whole blood. (B) A representative image of the immunofluores-
cence of pancreatic islets from WT mice showing that PCSK9 is expressed in d cells (somatostatin) (light blue staining in the overlay) are shown. (C)
PCSK9 mRNA expression in the liver or in the pancreas of AlbCreþ/Pcsk9LoxP/LoxP and AlbCre-/Pcsk9LoxP/LoxP mice are shown (data are shown as mean
± standard deviation, n= 5) (*P< 0.05), while (D) PCSK9 protein expression in the pancreatic islets from the same animals (the maximum intensity
projection of serial confocal sections is shown) are shown. Scale bar: 20lm. Low-density lipoprotein receptor expression in pancreatic b cells is
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expression should be associated with altered glucose metabolism.
Indeed, LOF variants in the HMGCoA reductase which, by limiting
cellular cholesterol biosynthesis, favor cholesterol uptake via LDLR
are associated with increased risk of developing diabetes,17 and the
5 same is true for LOF variants in PCSK9.17,18 More interestingly, when
the genetic effect of LOF variants in HMGCoA reductase coexists
with LOF variants of PCSK9, the risk of developing diabetes is further
increased.17 In line with this, FH subjects bearing a loss of function
mutation in the LDLR present a decreased risk of diabetes.20 Also,
10 pharmacological treatments resulting in increased LDLR expression,
such as statins, increase the risk of diabetes,27 thus indicating that ex-
cessive LDLR activity could be the driver of b-cell dysfunction and
diabetes. On these premises and given the great interest in anti-
PCSK9 therapies, we investigated in detail how PCSK9 deficiency
15 could affect glucose metabolism.
We show here that Pcsk9 KO mice present with impaired glucose
tolerance, independent of the type of diet used (high fat or standard
fat) but no insulin resistance. Previous findings on Pcsk9 KO are con-
trasting with a work reporting altered glucose metabolism following
20 oral glucose tolerance test in Pcsk9 KO mice compared to litter-
mates15 and another reporting no difference between WT and Pcsk9
KO following intraperitoneal GTT.26 Here, we take these observa-
tions forward by showing that Pcsk9 KO present decreased plasma
insulin and C-peptide levels, a finding paralleled by altered pancreatic
25 morphology and cholesterol esters accumulation, larger islets, and
increased insulin content. The increase in cholesterol esters might
mirror the intracellular response aimed at mitigating free
cholesterol cell toxicity which might result in the long term in b-cell
apoptosis.22–24 This molecular adaptation might occur together with
30 cellular reprogramming to increase cholesterol efflux.
Of note, under hypercholesterolaemic conditions, selective b-cell
ABCA-1 deficiency favours cholesterol accumulation in b cells, which
associates to impaired insulin secretion.28 The LDLR plays a key role
in determining b-cell dysfunction under hypercholesterolaemic condi-
35 tions29 and Ldlr KO mice transplanted with WT islets with functional
LDL present a normal functionality,29 suggesting that compensatory
mechanisms can maintain islet cholesterol homeostasis in this setting.
These observations suggest that both cholesterol uptake and efflux
are critical in maintaining a proper b-cell functionality.
40 It is important to stress that mice transport cholesterol mainly
through HDL and that Pcsk9 KO mice present a significant reduction
in cholesterol distribution in HDL25 coupled with decreased levels of
apoE-containing HDL and reduced efflux capacity.30 It is, therefore,
possible that also a decrease in HDL might contribute to cholesterol
45 accumulation in b cells. Furthermore, the differences in lipids and lip-
oproteins metabolism in mice (based mainly on ApoA-I and ApoE
containing liproproteins) compared with humans (based mainly on
ApoB containing lipoproteins) suggest the need to further address
the crosstalk among these pathways. Pcsk9 KO presented glucose in-
50tolerance when they were fed with either an SFD or an HFD; to limit
the implications of insulin resistance driven by HFD, we performed
most of the experiments on mice fed with an SFD. This does not ex-
clude the possibility that on a longer time point, the development of
metabolic abnormalities, as a consequence of HDF feeding, might
55mask part of the differences observed.
The presence of impaired b-cell function in Pcsk9 KO mice was
further confirmed in humans, where subjects with a PCSK9 LOF vari-
ant presented decreased HOMA-BC but not HOMA-IR compared
with age and sex matched carriers of the common allele.
60The study of glucose metabolism in Pcsk9/LdlrDKO mice showed that
it is the PCSK9-LDLR axis and not the other known targets of PCSK9
such as the very low-density lipoprotein receptor, the apolipoprotein E
receptor 2 (ApoER2), or cluster of differentiation 36 (CD36)31–34 to be
responsible for the phenotype observed in Pcsk9 KO mice.
65This observation is critical given that anti-PCSK9 therapies have
been recently approved for the treatment of FH and patients at very
high cardiovascular risk. It is possible that, while on the one hand anti-
PCSK9 therapies will reduce LDL-C levels and related mortality, on
the other hand they increase the risk of diabetes. Data available so far
70with anti-PCSK9 therapies (up to 2.2 years of treatment) do not
show an increased incidence of diabetes compared with the group
under standard therapy,35,36 although a recent meta-analysis showed
a significant increase in plasma glycaemia and glycated haemoglobin in
patients treated with PCSK9 inhibitors that, however, was not suffi-
75cient to increase the incidence of diabetes.37 Whether this effect
might appear after longer term treatments remains to be addressed.
Our data in PCSK9 tissue selective knock-out mice suggest an alter-
native explanation. Liver-selective Pcsk9KO mice have PCSK9 plasma
levels below the detection limit while maintaining PCSK9 production
80in other tissues including the pancreas. This setting closely mimics the
conditions of patients treated with anti-PCSK9 antibodies where
PCSK9 is absent the circulation, but it is still produced in extrahepatic
tissues, in contrast to the genetic studies with PCSK9 LOF where all
tissues present with a PCSK9-deficient condition. Liver-selective
85Pcsk9 KO mice present plasma and pancreatic insulin levels, LDLR ex-
pression as well as pancreatic islets cholesterol esters levels similar to
those of control mice; accordingly, also glucose tolerance and insulin
tolerance did not differ. These data indicate that circulating PCSK9
has a minimal if any effect on LDLR in pancreas and suggest the possi-
90bility that anti-PCSK9 therapies which target circulating PCSK9 might
have a limited impact on LDLR expression in pancreas. Whether this
is true also for gene-silencing approaches remains to be addressed.
Figure 6 Continued
shown in panel (E) as overlay of LDLR mean fluorescence intensity in AlbCre-/Pcsk9LoxP/LoxP, AlbCreþ/Pcsk9LoxP/LoxP, and Ldlr KO (12 weeks of
diet). (F) Plasma glucose levels in AlbCreþ/Pcsk9LoxP/LoxP and AlbCre-/Pcsk9LoxP/LoxP mice following intraperitoneal glucose tolerance test (0, 20,
40, 60, and 120 min) (no significant differences were observed between groups, P> 0.05) are shown. (G) Plasma glucose levels in AlbCreþ/
Pcsk9LoxP/LoxP and AlbCre-/Pcsk9LoxP/LoxP mice following intraperitoneal insulin tolerance test (0, 20, 40, 60, and 120 min) (no significant differen-
ces were observed between groups, P> 0.05) are shown.
10 L. Da Dalt et al.
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..In summary, PCSK9 critically controls LDLR expression in pan-
creas perhaps contributing to the maintenance of a proper physio-
logical balance to limit cholesterol overload in b cells. Pcsk9
deficiency in turn results in increased LDLR expression and choles-
5 terol esters accumulation in pancreatic islets, which impairs insulin se-
cretion (Take home figure). Future studies should aim at addressing in
humans the long-term safety of targeting circulating PCSK9 on pan-
creatic b-cell function.
Supplementary material
10Supplementary material is available at European Heart Journal online.
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